Improving Drug Delivery for Alzheimer’s Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels

References

• Association As. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15(3):321–387.
   Google Scholar
• Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2019;31(1):83–90. doi:10.1017/S1041610218000534
   PubMed Web of Science ®Google Scholar
• Tan JZA, Gleeson PA. The role of membrane trafficking in the processing of amyloid precursor protein and production of amyloid peptides in Alzheimer’s disease. Biochim Biophys Acta. 2019;1861(4):697–712. doi:10.1016/j.bbamem.2018.11.013
   Google Scholar
• Sharma P, Srivastava P, Seth A, Tripathi PN, Banerjee AG, Shrivastava SK. Comprehensive review of mechanisms of pathogenesis involved in Alzheimer’s disease and potential therapeutic strategies. Prog Neurobiol. 2019;174:53–89.
   PubMed Web of Science ®Google Scholar
• Sochocka M, Donskow-łysoniewska K, Diniz BS, Kurpas D, Brzozowska E, Leszek J. The gut microbiome alterations and inflammation-driven pathogenesis of Alzheimer’s disease—a critical review. Mol Neurobiol. 2019;56(3):1841–1851. doi:10.1007/s12035-018-1188-4
   PubMed Web of Science ®Google Scholar
• Webers A, Heneka MT, Gleeson PA. The role of innate immune responses and neuroinflammation in amyloid accumulation and progression of Alzheimer’s disease. Immunol Cell Biol. 2020;98(1):28–41. doi:10.1111/imcb.12301
   PubMed Web of Science ®Google Scholar
• Bradburn S, Murgatroyd C, Ray N. Neuroinflammation in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Ageing Res Rev. 2019;50:1–8. doi:10.1016/j.arr.2019.01.002
   PubMed Web of Science ®Google Scholar
• Atri A. Current and future treatments in Alzheimer’s Disease. Semin Neurol. 2019;39(2):227–240. doi:10.1055/s-0039-1678581
   PubMed Web of Science ®Google Scholar
• Reynolds DS. A short perspective on the long road to effective treatments for Alzheimer’s disease. Br J Pharmacol. 2019;176(18):3636–3648. doi:10.1111/bph.14581
   PubMedGoogle Scholar
• Grodzicki W, Dziendzikowska K. The role of selected bioactive compounds in the prevention of Alzheimer’s disease. Antioxidants. 2020;9(3):229. doi:10.3390/antiox9030229
   Web of Science ®Google Scholar
• Li R, Zhang Y, Rasool S, Geetha T, Babu JR. Effects and underlying mechanisms of bioactive compounds on type 2 diabetes mellitus and Alzheimer’s disease. In: Jakovljevic V, editor. Oxidative Medicine and Cellular Longevity. 2019.
   Google Scholar
• Saxena C, Arora K, Chaurasia L. Importance of different novel nasal drug delivery system-A Review. Int J Pharm Clin Res. 2019;11(1):13–19.
   Google Scholar
• Moinuddin S, Razvi S, Uddin MS, Fazil M, Shahidulla S, Akmal MM. Nasal drug delivery system: a innovative approach. J Pharm Innov. 2019;8(3):169–177.
   Google Scholar
• Schwarz B, Merkel OM. Nose-to-brain delivery of biologics. Fut Sci. 2019.
   Google Scholar
• Giunchedi P, Gavini E, Bonferoni MC Nose-to-Brain Delivery. Multidisciplinary Digital Publishing Institute; 2020.
   Google Scholar
• Theochari I, Xenakis A, Papadimitriou V. Nanocarriers for effective drug delivery. In: Nguyen-Tri P, Do TO, Nguyen TA, editors. Smart Nanocontainers. Elsevier; 2020:315–341.
   Google Scholar
• Singh AK, Yadav TP, Pandey B, Gupta V, Singh SP. Engineering Nanomaterials for Smart Drug Release: recent Advances and Challenges. In: Mohapatra M, Ranjan S, Dasgupta N, Mishra R, Thomas S, editors. Applications of Targeted Nano Drugs and Delivery Systems. Elsevier; 2019:411–449.
   Google Scholar
• Guideline IHT. Pharmaceutical development. In: Q8 (R2) Current Step. PharmaLogika, Inc.; 2009:4.
   Google Scholar
• Guideline IHT. Pharmaceutical quality system q10. In: Current Step. ICH Expert Working Group; 2008:4.
   Google Scholar
• Guideline IHT. Quality risk management. In: Q9, Current Step. 2005, 4;408.
   Google Scholar
• Cunha S, Costa CP, Moreira JN, Lobo JMS, Silva AC. Using the quality by design (QbD) approach to optimize formulations of lipid nanoparticles and nanoemulsions: a review. Nanomedicine. 2020;28:102206. doi:10.1016/j.nano.2020.102206
   PubMed Web of Science ®Google Scholar
• Iqbal B, Ali J, Baboota S. Silymarin loaded nanostructured lipid carrier: from design and dermatokinetic study to mechanistic analysis of epidermal drug deposition enhancement. J Mol Liq. 2018;255:513–529. doi:10.1016/j.molliq.2018.01.141
   Web of Science ®Google Scholar
• Shah B, Khunt D, Bhatt H, Misra M, Padh H. Application of quality by design approach for intranasal delivery of rivastigmine loaded solid lipid nanoparticles: effect on formulation and characterization parameters. Eur J Pharm Sci. 2015;78:54–66. doi:10.1016/j.ejps.2015.07.002
   PubMed Web of Science ®Google Scholar
• Han JY, Besser LM, Xiong C, Kukull WA, Morris JC. Cholinesterase inhibitors may not benefit mild cognitive impairment and mild Alzheimer disease dementia. Alzheimer Dis Assoc Disord. 2019;33(2):87. doi:10.1097/WAD.0000000000000291
   PubMed Web of Science ®Google Scholar
• Sharma P, Tripathi MK, Shrivastava SK. Cholinesterase as a target for drug development in Alzheimer’s Disease. In: Labrou N, editor. Targeting Enzymes for Pharmaceutical Development. Springer; 2020:257–286.
   Google Scholar
• Sharma K. Cholinesterase inhibitors as Alzheimer’s therapeutics. Mol Med Rep. 2019;20(2):1479–1487. doi:10.3892/mmr.2019.10374
   PubMed Web of Science ®Google Scholar
• Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: reevaluating the amyloid cascade hypothesis. Alzheimers Dement. 2019.
   Google Scholar
• Castellani RJ, Plascencia-Villa G, Perry G. The amyloid cascade and Alzheimer’s disease therapeutics: theory versus observation. Lab Invest. 2019;99(7):958–970. doi:10.1038/s41374-019-0231-z
   PubMed Web of Science ®Google Scholar
• Cunha S, Almeida H, Amaral M, Lobo JS, Silva A. Intranasal lipid nanoparticles for the treatment of neurodegenerative diseases. Curr Pharm Des. 2017;23(43):6553–6562. doi:10.2174/1381612824666171128105305
   Google Scholar
• Yang LY, Greig NH, Tweedie D, et al. The p53 inactivators pifithrin-mu and pifithrin-alpha mitigate TBI-induced neuronal damage through regulation of oxidative stress, neuroinflammation, autophagy and mitophagy. Exp Neurol. 2020;324:113135. doi:10.1016/j.expneurol.2019.113135
   PubMedGoogle Scholar
• Gao Q. Oxidative stress and autophagy. In: Qin ZH, editor. Autophagy: Biology and Diseases. Springer; 2019:179–198.
   Google Scholar
• Vasantharaja R, Stanley Abraham L, Gopinath V, Hariharan D, Smita KM. Attenuation of oxidative stress induced mitochondrial dysfunction and cytotoxicity in fibroblast cells by sulfated polysaccharide from Padina gymnospora. Int J Biol Macromol. 2019;124:50–59. doi:10.1016/j.ijbiomac.2018.11.104
   PubMed Web of Science ®Google Scholar
• Zokaei N, Cepukaityte G, Board AG, Mackay CE, Husain M, Nobre AC. Dissociable effects of the apolipoprotein-E (APOE) gene on short- and long-term memories. Neurobiol Aging. 2019;73:115–122. doi:10.1016/j.neurobiolaging.2018.09.017
   PubMedGoogle Scholar
• Suidan GL, Ramaswamy G. Targeting Apolipoprotein E for Alzheimer’s Disease: an industry perspective. Int J Mol Sci. 2019;20(9):2161. doi:10.3390/ijms20092161
   PubMedGoogle Scholar
• Tzioras M, Davies C, Newman A, Jackson R, Spires-Jones T. Invited Review: APOE at the interface of inflammation, neurodegeneration and pathological protein spread in Alzheimer’s disease. Neuropathol Appl Neurobiol. 2019;45(4):327–346. doi:10.1111/nan.12529
   PubMedGoogle Scholar
• Voet S, Srinivasan S, Lamkanfi M, van Loo G. Inflammasomes in neuroinflammatory and neurodegenerative diseases. EMBO Mol Med. 2019;11(6):Jun. doi:10.15252/emmm.201810248
   Google Scholar
• Ceyzeriat K, Zilli T, Millet P, Frisoni GB, Garibotto V, Tournier BB. Learning from the past: a review of clinical trials targeting amyloid, tau and neuroinflammation in Alzheimer’s Disease. Curr Alzheimer Res. 2020;17(2):112–125. doi:10.2174/1567205017666200304085513
   PubMedGoogle Scholar
• Kaur D, Sharma V, Deshmukh R. Activation of microglia and astrocytes: a roadway to neuroinflammation and Alzheimer’s disease. Inflammopharmacology. 2019;27(4):663–677. doi:10.1007/s10787-019-00580-x
   PubMed Web of Science ®Google Scholar
• Lautrup S, Lou G, Aman Y, Nilsen H, Tao J, Fang EF. Microglial mitophagy mitigates neuroinflammation in Alzheimer’s disease. Neurochem Int. 2019;129:104469. doi:10.1016/j.neuint.2019.104469
   PubMedGoogle Scholar
• Walker KA, Ficek BN, Westbrook R. Understanding the Role of Systemic Inflammation in Alzheimer’s Disease. ACS Publications; 2019.
   Google Scholar
• Paouri E, Georgopoulos S. Systemic and CNS inflammation crosstalk: implications for Alzheimer’s Disease. Curr Alzheimer Res. 2019;16(6):559–574. doi:10.2174/1567205016666190321154618
   PubMed Web of Science ®Google Scholar
• Cabrera-Pastor A, Llansola M, Montoliu C, et al. Peripheral inflammation induces neuroinflammation that alters neurotransmission and cognitive and motor function in hepatic encephalopathy: underlying mechanisms and therapeutic implications. Acta Physiol (Oxf). 2019;226(2):e13270. doi:10.1111/apha.13270
   PubMedGoogle Scholar
• Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV. Blood-brain barrier: from physiology to disease and back. Physiol Rev. 2019;99(1):21–78. doi:10.1152/physrev.00050.2017
   PubMed Web of Science ®Google Scholar
• Berhe AG, Tafere NA, Gebremariam BM, Beyene HA. Review on functional and histological effect of lead on the central nervous system. RRJoNS. 2020;9(3):29–33.
   Google Scholar
• Charabati M, Rabanel J-M, Ramassamy C, Prat A. Overcoming the brain barriers: from immune cells to nanoparticles. Trends Pharmacol Sci. 2019;41(1):42–54. doi:10.1016/j.tips.2019.11.001
   PubMedGoogle Scholar
• Brito MA. Blood–Brain Barrier in Alzheimer’s Disease. In: Fink G, editor. Stress: Physiology, Biochemistry, and Pathology. Elsevier; 2019:337–348.
   Google Scholar
• Beccaria K, Canney M, Bouchoux G, Puget S, Grill J, Carpentier A. Blood-brain barrier disruption with low-intensity pulsed ultrasound for the treatment of pediatric brain tumors: a review and perspectives. Neurosurg Focus. 2020;48(1):E10. doi:10.3171/2019.10.FOCUS19726
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Blood-Brain Barrier and delivery of protein and gene therapeutics to brain. Front Aging Neurosci. 2020;11:373. doi:10.3389/fnagi.2019.00373
   PubMed Web of Science ®Google Scholar
• D’Amico RS, Khatri D, Reichman N, et al. Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going. J Neurooncol. 2020;1–18.
   Google Scholar
• Beccaria K, Sabbagh A, de Groot J, Canney M, Carpentier A, Heimberger AB. Blood–brain barrier opening with low intensity pulsed ultrasound for immune modulation and immune therapeutic delivery to CNS tumors. J Neurooncol. 2020;1–9.
   Google Scholar
• Zhang P, Xu S, Zhu Z, Xu J. Multi-target design strategies for the improved treatment of Alzheimer’s disease. Eur J Med Chem. 2019;176:228–247. doi:10.1016/j.ejmech.2019.05.020
   PubMed Web of Science ®Google Scholar
• Haake A, Nguyen K, Friedman L, Chakkamparambil B, Grossberg GT. An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer’s disease. Expert Opin Drug Saf. 2020;19(2):147–157. doi:10.1080/14740338.2020.1721456
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration (FDA). Aricep® (donepezil hydrochloride) tablets; 2012 [ cited 2020 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/020690s035,021720s008,022568s005lbl.pdf. Accessed May 28, 2021.
   Google Scholar
• Food and Drug Administration (FDA). Reminyl® (galantamine hydrobromide) Tablets; 2001 [ cited 2020 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2001/21-224_REMINYL_biopharmr.pdf. Accessed May 28, 2021.
   Google Scholar
• Food and Drug Administration (FDA). Razadyne®ER and Razadyne® (galantamine hydrobromide); 2017 [ cited 2020 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021169Orig1s032,021224Orig1s030,021615Orig1s023lbl.pdf. Accessed May 28, 2021.
   Google Scholar
• European Medicines Agency (EMA). Prometax® (rivastigmine); 2012 [ cited 2020 July 15]. Available from: https://www.ema.europa.eu/en/documents/overview/prometax-epar-summary-public_en.pdf. Accessed May 28, 2021.
   Google Scholar
• Food and Drug Administration (FDA): Exelon® (rivastigmine tartrate) Capsules and Oral Solution; 2006 [ cited 2020 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/020823s016,021025s008lbl.pdf. Accessed May 28, 2021.
   Google Scholar
• Food and Drug Administration (FDA). Exelon® Patch (rivastigmine transdermal system); 2007 [ cited 2020 July 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/022083lbl.pdf. Accessed May 28, 2021.
   Google Scholar
• European Medicines Agency (EMA). Ebixa (cloridrato de memantina); 2011 [ cited 2020 July 15]. Available from: https://www.ema.europa.eu/en/documents/overview/ebixa-epar-summary-public_pt.pdf. Accessed May 28, 2021.
   Google Scholar
• European Medicines Agency (EMA). Axura® (memantine hydrochloride); 2011 [ cited 2020 July 15]. https://www.ema.europa.eu/en/documents/overview/axura-epar-summary-public_en.pdf. Accessed May 28, 2021.
   Google Scholar
• Ray B, Maloney B, Sambamurti K, et al. Rivastigmine modifies the alpha-secretase pathway and potentially early Alzheimer’s disease. Transl Psychiatry. 2020;10(1):47. doi:10.1038/s41398-020-0709-x
   PubMed Web of Science ®Google Scholar
• Grossberg GT, Tong G, Burke AD, Tariot PN. Present algorithms and future treatments for Alzheimer’s Disease. J Alzheimers Dis. 2019;67(4):1157–1171. doi:10.3233/jad-180903
   PubMed Web of Science ®Google Scholar
• Iraji A, Khoshneviszadeh M, Firuzi O, Khoshneviszadeh M, Edraki N. Novel Small Molecule Therapeutic Agents for Alzheimer Disease: focusing on BACE1 and multi-target directed ligands. Bioorg Chem. 2020;103649.
   PubMedGoogle Scholar
• Schneider L. A resurrection of aducanumab for Alzheimer’s disease. Lancet Neurol. 2020;19(2):111–112. doi:10.1016/S1474-4422(19)30480-6
   PubMed Web of Science ®Google Scholar
• Cremonini AL, Caffa I, Cea M, Nencioni A, Odetti P, Monacelli F. Nutrients in the prevention of Alzheimer’s Disease. Oxid Med Cell Longev. 2019;2019:1–20. doi:10.1155/2019/9874159
   Google Scholar
• Thuphairo K, Sornchan P, Suttisansanee U. Bioactive compounds, antioxidant activity and inhibition of key enzymes relevant to Alzheimer’s disease from sweet pepper (Capsicum annuum) extracts. Prevent Nutr Food Sci. 2019;24(3):327. doi:10.3746/pnf.2019.24.3.327
   PubMedGoogle Scholar
• Serafini MM, Catanzaro M, Rosini M, Racchi M, Lanni C. Curcumin in Alzheimer’s disease: can we think to new strategies and perspectives for this molecule? Pharmacol Res. 2017;124:146–155. doi:10.1016/j.phrs.2017.08.004
   PubMed Web of Science ®Google Scholar
• Rajput AP, Butani SB. Resveratrol anchored nanostructured lipid carrier loaded in situ gel via nasal route: formulation, optimization and in vivo characterization. J Drug Deliv Sci Technol. 2019;51:214–223. doi:10.1016/j.jddst.2019.01.040
   Web of Science ®Google Scholar
• Pinheiro R, Granja A, Loureiro J, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s disease. Eur J Pharm Sci. 2020;148:105314. doi:10.1016/j.ejps.2020.105314
   PubMed Web of Science ®Google Scholar
• Ahmad N, Ahmad R, Ahmad FJ, et al. Poloxamer-chitosan-based Naringenin nanoformulation used in brain targeting for the treatment of cerebral ischemia. Saudi J Biol Sci. 2020;27(1):500–517. doi:10.1016/j.sjbs.2019.11.008
   PubMed Web of Science ®Google Scholar
• Landel V, Annweiler C, Millet P, Morello M, Féron F. Vitamin D, cognition and Alzheimer’s Disease: the therapeutic benefit is in the D-Tails. J Alzheimers Dis. 2016;53(2):419–444. doi:10.3233/JAD-150943
   PubMed Web of Science ®Google Scholar
• Casati M, Boccardi V, Ferri E, et al. Vitamin E and Alzheimer’s disease: the mediating role of cellular aging. Aging Clin Exp Res. 2020;32(3):459–464. doi:10.1007/s40520-019-01209-3
   PubMed Web of Science ®Google Scholar
• Gupta S, Kumar S. An overview on intranasal drug delivery system: recent technique and its contribution in therapeutic management. Curr Res Pharm Sci. 2019.
   Google Scholar
• Jadhav S, Sahoo S, Mishra SK. A Review: nose to brain drug delivery for various CNS disorders. In: Pawar PM, Balasubramaniam R, Ronge BP, Salunkhe SB, Vibhute AS, Melinamath B, editors. Techno-Societal 2018. Springer; 2020:375–385.
   Google Scholar
• Akel H, Ismail R, Csóka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. Eur J Pharm Biopharm. 2020;148:38–53. doi:10.1016/j.ejpb.2019.12.014
   PubMed Web of Science ®Google Scholar
• Cunha S, Amaral MH, Lobo JS, Silva AC. Lipid nanoparticles for nasal/intranasal drug delivery. Crit Rev Ther Drug Carrier Syst. 2017;34(3):3. doi:10.1615/CritRevTherDrugCarrierSyst.2017018693
   Google Scholar
• Martins PP, Smyth HD, Cui Z. Strategies to facilitate or block nose-to-brain drug delivery. Int J Pharm. 2019;570:118635. doi:10.1016/j.ijpharm.2019.118635
   PubMed Web of Science ®Google Scholar
• Costa C, Moreira J, Amaral M, Lobo JS, Silva A. Nose-to-brain delivery of lipid-based nanosystems for epileptic seizures and anxiety crisis. J Control Release. 2019;295:187–200. doi:10.1016/j.jconrel.2018.12.049
   PubMed Web of Science ®Google Scholar
• Lochhead JJ, Davis TP. Perivascular and Perineural pathways involved in brain delivery and distribution of drugs after intranasal administration. Pharmaceutics. 2019;11(11):598. doi:10.3390/pharmaceutics11110598
   PubMedGoogle Scholar
• Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci. 2008;9(S3):S5. doi:10.1186/1471-2202-9-S3-S5
   PubMedGoogle Scholar
• Cunha S, Costa CP, Loureiro JA, et al. Double optimization of rivastigmine-loaded Nanostructured Lipid Carriers (NLC) for nose-to-brain delivery using the Quality by Design (QbD) approach: formulation variables and instrumental parameters. Pharmaceutics. 2020;12(7):599. doi:10.3390/pharmaceutics12070599
   PubMed Web of Science ®Google Scholar
• Dos Passos Menezes P, de Araújo Andrade T, La F, et al. Advances of nanosystems containing cyclodextrins and their applications in pharmaceuticals. Int J Pharm. 2019.
   Google Scholar
• Chavda VP. Nanobased nano drug delivery: a comprehensive Review. In: Mohapatra S, Ranjan S, Dasgupta N, Kumar R,  Thomas S, editors. Applications of Targeted Nano Drugs and Delivery Systems. Elsevier; 2019:69–92.
   Google Scholar
• Shaker DS, Ishak RA, Ghoneim A, Elhuoni MA. Nanoemulsion: a review on mechanisms for the transdermal delivery of hydrophobic and hydrophilic drugs. Sci Pharm. 2019;87(3):17. doi:10.3390/scipharm87030017
   Web of Science ®Google Scholar
• Jiang T, Liao W, Charcosset C. Recent advances in encapsulation of curcumin in nanoemulsions: a review of encapsulation technologies, bioaccessibility and applications. Food Res Int. 2020;132:109035. doi:10.1016/j.foodres.2020.109035
   PubMed Web of Science ®Google Scholar
• Gupta A. Nanoemulsions. In: Chung EJ, Leon L, Rinaldi C, editors. Nanoparticles for Biomedical Applications. Elsevier; 2020:371–384.
   Google Scholar
• Nirale P, Paul A, Yadav KS. Nanoemulsions for targeting the neurodegenerative diseases: alzheimer’s, Parkinson’s and Prion’s. Life Sci. 2020;245:117394. doi:10.1016/j.lfs.2020.117394
   PubMedGoogle Scholar
• Silva A, González-Mira E, Lobo JS, Amaral M. Current progresses on nanodelivery systems for the treatment of neuropsychiatric diseases: alzheimer’s and Schizophrenia. Curr Pharm Des. 2013;19(41):7185–7195. doi:10.2174/138161281941131219123329
   PubMed Web of Science ®Google Scholar
• Silva A, Santos D, Ferreira D, Lopes CM. Lipid-based nanocarriers as an alternative for oral delivery of poorly water-soluble drugs: peroral and mucosal routes. Curr Med Chem. 2012;19(26):4495–4510. doi:10.2174/092986712803251584
   PubMed Web of Science ®Google Scholar
• Bhosale RR, Osmani RA, Ghodake PP, Shaikh SM, Chavan SR. Nanoemulsion: a review on novel profusion in advanced drug delivery. Indian J Pharmaceut Biol Res. 2014;2(01):122–127. doi:10.30750/ijpbr.2.1.19
   Google Scholar
• Bonferoni MC, Rossi S, Sandri G, et al. Nanoemulsions for “nose-to-brain” drug delivery. Pharmaceutics. 2019;11(2):84. doi:10.3390/pharmaceutics11020084
   PubMedGoogle Scholar
• Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: available proof of concept and existing challenges. Int J Pharm. 2019;565:258–268. doi:10.1016/j.ijpharm.2019.05.032
   PubMed Web of Science ®Google Scholar
• Karami Z, Zanjani MRS, Hamidi M. Nanoemulsions in CNS drug delivery: recent developments, impacts and challenges. Drug Discov Today. 2019;24(5):1104–1115. doi:10.1016/j.drudis.2019.03.021
   PubMedGoogle Scholar
• Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: a Review. Pharmaceutics. 2020;12(3):288. doi:10.3390/pharmaceutics12030288
   PubMed Web of Science ®Google Scholar
• Beloqui A, Solinís MÁ, Rodríguez-Gascón A, Almeida AJ, Préat V. Nanostructured lipid carriers: promising drug delivery systems for future clinics. Nanomedicine. 2016;12(1):143–161. doi:10.1016/j.nano.2015.09.004
   PubMed Web of Science ®Google Scholar
• Alam MI, Baboota S, Ahuja A, Ali M, Ali J, Sahni JK. Intranasal administration of nanostructured lipid carriers containing CNS acting drug: pharmacodynamic studies and estimation in blood and brain. J Psychiatr Res. 2012;46(9):1133–1138. doi:10.1016/j.jpsychires.2012.05.014
   PubMed Web of Science ®Google Scholar
• Elmowafy M, Shalaby K, Badran MM, Ali HM, Abdel-Bakky MS, Ibrahim HM. Multifunctional carbamazepine loaded nanostructured lipid carrier (NLC) formulation. Int J Pharm. 2018;550(1–2):359–371. doi:10.1016/j.ijpharm.2018.08.062
   PubMed Web of Science ®Google Scholar
• Gadhave DG, Kokare CR. Nanostructured lipid carriers engineered for intranasal delivery of teriflunomide in multiple sclerosis: optimization and in vivo studies. Drug Dev Ind Pharm. 2019;45(5):839–851. doi:10.1080/03639045.2019.1576724
   PubMed Web of Science ®Google Scholar
• Desfrançois C, Auzély R, Texier I. Lipid nanoparticles and their hydrogel composites for drug delivery: a review. Pharmaceuticals. 2018;11(4):118. doi:10.3390/ph11040118
   Web of Science ®Google Scholar
• Sabale AS, Kulkarni AD, Sabale AS. Nasal in situ gel: novel approach for nasal drug delivery. J Drug Deliv Ther. 2020;10(2–s):183–197. doi:10.22270/jddt.v10i2-s.4029
   Google Scholar
• Adnet T, Groo A-C, Picard C, et al. Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for Alzheimer’s Disease Treatment. Pharmaceutics. 2020;12(3):251. doi:10.3390/pharmaceutics12030251
   PubMed Web of Science ®Google Scholar
• Makhlouf ASH, Perez A, Guerrero E. Recent trends in smart polymeric coatings in biomedicine and drug delivery applications. In: Makhlouf ASH,  Abu-Thabit NY, editors. Advances in Smart Coatings and Thin Films for Future Industrial and Biomedical Engineering Applications. Elsevier; 2020:359–381.
   Google Scholar
• Guha A, Shaharyar MA, Ali KA, Roy SK, Kuotsu K. Smart and intelligent stimuli responsive materials: an innovative step in drug delivery system. Curr Biochem Eng. 2020;6(1):41–52. doi:10.2174/2212711906666190723142057
   Google Scholar
• Sun R, Xia Q. Release mechanism of lipid nanoparticles immobilized within alginate beads influenced by nanoparticle size and alginate concentration. Colloid Polym Sci. 2019;297(9):1183–1198. doi:10.1007/s00396-019-04538-x
   Google Scholar
• Grangeia HB, Silva C, Simões SP, Reis MS. Quality by design in pharmaceutical manufacturing: a systematic review of current status, challenges and future perspectives. Eur J Pharm Biopharm. 2019;147:19–37. doi:10.1016/j.ejpb.2019.12.007
   PubMedGoogle Scholar
• Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: design, characterization, and in vivo study. Drug Deliv. 2016;23(4):1326–1334. doi:10.3109/10717544.2014.975382
   PubMed Web of Science ®Google Scholar
• Fachel FNS, Dal Prá M, Azambuja JH, et al. Glioprotective effect of chitosan-coated rosmarinic acid nanoemulsions against lipopolysaccharide-induced inflammation and oxidative stress in rat astrocyte primary cultures. Cell Mol Neurobiol. 2020;40(1):123–139. doi:10.1007/s10571-019-00727-y
   PubMedGoogle Scholar
• Kaur A, Nigam K, Bhatnagar I, et al. Treatment of Alzheimer’s diseases using donepezil nanoemulsion: an intranasal approach. In: Alonso MJ, editor. Drug Delivery and Translational Research. 2020:1–14.
   Google Scholar
• Kaur A, Nigam K, Srivastava S, Tyagi A, Dang S. Memantine nanoemulsion: a new approach to treat Alzheimer’s disease. J Microencapsul. 2020;1–11.
   Google Scholar
• Jojo GM, Kuppusamy G, De A, Karri VNR. Formulation and optimization of intranasal nanolipid carriers of pioglitazone for the repurposing in Alzheimer’s disease using Box-Behnken design. Drug Dev Ind Pharm. 2019;45(7):1061–1072. doi:10.1080/03639045.2019.1593439
   PubMed Web of Science ®Google Scholar
• Anand A, Arya M, Kaithwas G, Singh G, Saraf SA. Sucrose stearate as a biosurfactant for development of rivastigmine containing nanostructured lipid carriers and assessment of its activity against dementia in C. elegans model. J Drug Deliv Sci Technol. 2019;49:219–226. doi:10.1016/j.jddst.2018.11.021
   Web of Science ®Google Scholar
• Pires PC, Peixoto D, Teixeira I, Rodrigues M, Alves G, Santos AO. Nanoemulsions and thermosensitive nanoemulgels of phenytoin and fosphenytoin for intranasal administration: formulation development and in vitro characterization. Eur J Pharmaceut Sci. 2020;141:105099. doi:10.1016/j.ejps.2019.105099
   PubMedGoogle Scholar
• Focused ultrasound foundation: blood-brain barrier opening; 2019 [ cited 2020 July 15].
   Google Scholar
• Hong -S-S, Oh KT, Choi H-G, Lim S-J. Liposomal formulations for nose-to-brain delivery: recent advances and future perspectives. Pharmaceutics. 2019;11(10):540. doi:10.3390/pharmaceutics11100540
   PubMed Web of Science ®Google Scholar